12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 825 participants.
Also called NCT01370005
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 825 participants
- Registry
-
NCT01370005 -
2011-000347-25
-
- Other papers using this trial's data
- Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension
- Impact of Empagliflozin on Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension by Background Antihypertensive Medication
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, Czechia, Denmark, Estonia, Finland, France, Germany, Lebanon, Netherlands, Norway, Sweden
- Registry status
- Completed
Technical summary
Registry record NCT01370005. Randomized; double masking; primary purpose treatment. Start 2011-06 (registry gives no type); primary completion 2012-07 (actual). Results posted on 2014-06-17.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- 12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus
- Condition
- Diabetes Mellitus, Type 2
- Condition
- Hypertension
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- BI 10773
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- BI 10773
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Placebo
- Lead sponsor
- Boehringer Ingelheim
- Collaborator
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct01370005- Content hash
b429e7ff7038a7d7eb0579ecd8edd82b3585a772bfc6f2712c402225d84ab491